Kirk Keegan III MD, MPH
Senior Medical Director
Janssen Research and Development
Medical School: Georgetown University, Washington D.C.
Residency: University of California, Davis
Fellowship: Vanderbilt University Medical Center
Active Clinical Trials
FKD Therapies/Instiladrin
A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN (rAd-IFN/Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
TAR-200
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) (SunRISe-5)